zongertinib (Hernexeos)
Jump to navigation
Jump to search
Indications
- adults with metastatic non-squamous NSCLC with HER2 mutations & who have received at least one prior line of platinum-based chemotherapy
Dosage
- 120 mg once daily (< 90 kg), 180 mg once daily (> 90 kg)
Tablets: 60 mg
Adverse effects
- most common (>= 20%)
- laboratory abnormalities
- decreased lymphocyte count, increased serum ALT, increased serum AST, hypokalemia, increased serum GGT
Mechanism of action
- tyrosine kinase inhibitor
- selectively targets HER2
More general terms
References
- ↑ Heymach JV, Ruiter G, Ahn MJ et al; Beamion LUNG-1 Investigators. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025 Jun 19;392(23):2321-2333. PMID: https://pubmed.ncbi.nlm.nih.gov/40293180 Clinical Trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2503704